Viracor Eurofins announced the launch of predictive acute graft-versus-host disease (aGVHD) algorithms to help identify at-risk patients.
aGVHD is a major complication following allogeneic hematopoietic cell transplantation (allo-HCT). Accurate and early identification of patients at high-risk for severe aGVHD and related complications has the potential to improve patient outcomes. High risk patients can be preemptively treated for aGVHD prior to the onset of clinical disease, while low-risk patients may potentially avoid unnecessary treatment.
Viracor's new aGVHD algorithm testing, which uses the Mount Sinai Acute GVHD International Consortium (MAGIC) algorithm, was developed by James Ferrara and John Levine, both professors of pediatrics, medicine, hematology and medical oncology at the Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai, and validated in conjunction with 17 hematopoietic cell transplantation centers. The aGVHD predictive algorithms use serum levels of ST2 and regenerating islet-derived 3-alpha biomarkers, which are interpreted through the MAGIC algorithm using clinically validated cutoff values specific to the time of sample collection and/or the patient's condition. Use of these predictive algorithms have been demonstrated to be accurate despite variations in clinical factors that increase the risk of non-relapse mortality post-transplant.
Viracor's three algorithms have been validated to risk stratify severe aGVHD and NRM at distinct events post-allogeneic HCT. The aGVHD presymptomatic algorithm is for use approximately seven days post-transplant, and before the patient shows onset of aGVHD symptoms. The aGVHD symptomatic onset algorithm is for use post-transplant after the patient begins to display symptoms of aGVHD. The aGVHD post-treatment algorithm is for use approximately seven days or more after systemic treatment for aGVHD has been initiated.
Viracor delivers results of these testing algorithms to physicians within 24 hours of receiving the specimen.